JP2007505885A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505885A5
JP2007505885A5 JP2006526717A JP2006526717A JP2007505885A5 JP 2007505885 A5 JP2007505885 A5 JP 2007505885A5 JP 2006526717 A JP2006526717 A JP 2006526717A JP 2006526717 A JP2006526717 A JP 2006526717A JP 2007505885 A5 JP2007505885 A5 JP 2007505885A5
Authority
JP
Japan
Prior art keywords
free acid
atorvastatin free
crystalline form
following
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002919 external-priority patent/WO2005026116A1/en
Publication of JP2007505885A publication Critical patent/JP2007505885A/ja
Publication of JP2007505885A5 publication Critical patent/JP2007505885A5/ja
Pending legal-status Critical Current

Links

JP2006526717A 2003-09-17 2004-09-06 [R−(R*,R*)]−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸の結晶性形態 Pending JP2007505885A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50359203P 2003-09-17 2003-09-17
PCT/IB2004/002919 WO2005026116A1 (en) 2003-09-17 2004-09-06 Crystalline forms of `r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid

Publications (2)

Publication Number Publication Date
JP2007505885A JP2007505885A (ja) 2007-03-15
JP2007505885A5 true JP2007505885A5 (cg-RX-API-DMAC7.html) 2007-10-25

Family

ID=34312443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526717A Pending JP2007505885A (ja) 2003-09-17 2004-09-06 [R−(R*,R*)]−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸の結晶性形態

Country Status (16)

Country Link
US (1) US20070276027A1 (cg-RX-API-DMAC7.html)
EP (1) EP1663969A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007505885A (cg-RX-API-DMAC7.html)
KR (1) KR100781420B1 (cg-RX-API-DMAC7.html)
CN (2) CN101318923A (cg-RX-API-DMAC7.html)
AR (1) AR045654A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004272365A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414457A (cg-RX-API-DMAC7.html)
CA (1) CA2539158A1 (cg-RX-API-DMAC7.html)
IL (1) IL173651A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003003A (cg-RX-API-DMAC7.html)
NO (1) NO20060716L (cg-RX-API-DMAC7.html)
RU (1) RU2315755C2 (cg-RX-API-DMAC7.html)
TW (1) TW200524862A (cg-RX-API-DMAC7.html)
WO (1) WO2005026116A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602222B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
JP2010523612A (ja) * 2007-04-13 2010-07-15 ニコックス エス エイ アトルバスタチン4−(ニトロオキシ)ブチルエステルの結晶形態
WO2010080971A1 (en) * 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
CA2706272C (en) 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681873A (en) * 1985-07-29 1987-07-21 Warner-Lambert Company 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5213995A (en) * 1992-04-16 1993-05-25 At&T Bell Laboratories Method of making an article comprising a periodic heteroepitaxial semiconductor structure
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
BR9609872A (pt) * 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
ES2176756T3 (es) * 1996-07-29 2002-12-01 Warner Lambert Co Proceso perfeccionado para la sintesis de los esteres protegidos del acido (s)-3,4-dihidroxibutirico.
AU755543B2 (en) * 1997-12-19 2002-12-12 Warner-Lambert Export Limited Process for the synthesis of 1,3-diols
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
HRP20030454A2 (en) * 2000-11-16 2005-10-31 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Similar Documents

Publication Publication Date Title
KR100431039B1 (ko) 결정질ⅲ형[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
ES2233526T3 (es) Sal hemicalcica del acido r-(r*,r*)### -2(4-fluorofenil)-beta, delta-dihidroxi 5-(1-metiletil)-3-fenil-4 (fenilamino) carbonil 1h-pirrolo-1-heptanoico cristalina.
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
CA2429844A1 (en) Mch antagonists and their use in the treatment of obesity
JP2012512885A5 (cg-RX-API-DMAC7.html)
IL226912A (en) The history of triazole, their preparation and their pharmaceutical preparations
EP1802588A1 (en) Substituted amino-pyrimidones and uses thereof
JP2009502743A5 (cg-RX-API-DMAC7.html)
MY141754A (en) Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions
CA2472954A1 (en) Aza-arylpiperazines
RS52663B2 (sr) Nova kristalna forma tiotropijum bromida i proces njene pripreme
CA2378382A1 (en) Carboxylic acid amides, pharmaceutical compositions containing these compounds, the use and preparation thereof
SI1598333T1 (sl) Postopek za pripravo (1s)-4,5-dimetoksi-1-(metilaminometil)-benzociklobutana in njegovih adicijskih soli, kot tudi uporaba za sintezo ivabradina in njegovih adicijskih soli s farmacevtsko sprejemljivo kislino
JP2009506014A5 (cg-RX-API-DMAC7.html)
JP2011140508A (ja) 安定なイマチニブ組成物
AU2021374260A9 (en) Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
RU2001123035A (ru) Химические соединения
ATE444806T1 (de) Dampfspaltungskatalysator und dessen herstellungsverfahren
IL266097B (en) Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
RU2006138497A (ru) Кристаллические формы n-десметилклозапина
JP2022525102A5 (cg-RX-API-DMAC7.html)
JP2008514558A5 (cg-RX-API-DMAC7.html)
WO2007002764A3 (en) Di-substituted oxadiazoles as cxc-chemokine receptor ligands
CN107980038A (zh) 沙库巴曲钙盐
HRP20000291B1 (en) High purity (1r, 2s, 4r)-(-)-2-/(2'-/n,n-dimethylamino/-ethoxy)/-2-/phenyl/-1,7,7-tri-/methyl/bicyclo/2.2.1/ heptane and pharmaceutically acceptable acid addition salts thereof and process for the preparation of these compounds as well medicaments containing one or more of them and the use thereof